Celularity vs DSS
CELU and DSS side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CELU and DSS compare
Celularity is the larger company, worth 5.1 times as much as DSS ($24.4M against $4.8M).
DSS grew revenue faster over the last twelve months (−13.2% versus −58.1% for Celularity).
Celularity scores higher on the StockData Score (7 against 1 for DSS), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CELU | DSS |
|---|---|---|
| Size and price | ||
| Market cap | $24.4M | $4.8M |
| Share price | $0.751 | $0.478 |
| Change, 1 year | −57.6% | −60.2% |
| Change, 5 years | −98.9% | −97.5% |
| Beta (5Y) | 1.96 | 0.56 |
| Employees | 115 | 102 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 1 | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 4 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.3× | 0.3× (better) |
| Growth | ||
| Revenue growth (TTM) | −58.1% | −13.2% (better) |
| Revenue growth, 5Y average | 13.2% (better) | 6.2% |
| Profitability | ||
| Gross margin | 19.2% | – |
| Operating margin | −264% | −89.7% (better) |
| Net margin | −246% | – |
| Return on invested capital | – | −284% |
| Financial health | ||
| Interest coverage | – | −69.6× |
| Current ratio | 0.11 | 0.19 (better) |
| Altman Z-score | −16.46 | −8.09 (better) |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 6.8% | 4.3% |
| Insider net buying, 12 months | – | −$17.9K |
Go deeper
- CELU stock overview
- CELU income statement
- CELU valuation and score
- DSS stock overview
- DSS income statement
- DSS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.